摘要:
The invention provides a method of treating viral haemorrhagic fevers, such as that caused by Dengue virus, which comprises administering a composition comprising a pharmaceutically active amount of a matrix metalloproteinase inhibitor.
摘要:
The invention relates to the use of IL-22 alone or in combination as biomarker of resistance to infections in humans when added to of one or several agonists of the formyl peptide receptors (FPR) receptors family and formyl peptide receptors-like 1 (FPRL 1). Said biomarker is useful in diagnostics, prophylaxis and therapeutics.